Impact of single use versus reuse of cellulose dialyzers on clinical parameters and indices of biocompatibility

Journal of the American Society of Nephrology

Volumn 7, Issue 6, 1996, Pages 861-870

  Pereira, Brian J G ^a   Natov, Svetlozar N ^a   Sundaram, Sumuk ^a   Schmid, Christopher H ^a   Trabelsi, Felice R ^b   Strom, James A ^b   King, Andrew J ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

Adequacy of dialysis; Biocompatibility; Cytokines; Reuse

Indexed keywords

ALBUMIN; CALCIUM; CHOLESTEROL; COMPLEMENT COMPONENT C3A; CYTOKINE; GLUTARALDEHYDE; INTERLEUKIN 1; PHOSPHORUS; PROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ARTIFICIAL KIDNEY; BIOCOMPATIBILITY; BLOOD CELL COUNT; CALCIUM BLOOD LEVEL; CHILL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; FEVER; HEMODIALYSIS; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; QUALITATIVE DIAGNOSIS; QUANTITATIVE DIAGNOSIS; RIGOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030366265     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Shaldon SH, Silva H, Rosen SM: The technique of refrigerated coil preservation hemodialysis with femoral venous catheterization. Br Med J 1964;2:672-674.
2. Pollard TL, Barnett BMS, Eschbach JW, Scribner BH: A technique for storage and multiple reuse of Kiil dialyzer and blood tubing. ASAIO (Am Soc Artif Intern Organs) Trans 1967;13:24-28.
3. Tokars JI, Alter MJ, Favero MS, Moyer LA, Bland LA: National surveillance of hemodialysis associated diseases in the United States, 1990. Trans Am Soc Artif Intern Org 1993;39:71-80.
4. Bland A: Hemodialysis reuse in the 1990's. Practice regulation and patients safety [1994]. Nephrol News Issues 1995;9:8-10.
5. Held PJ, Wolfe RA, Gaylin DS, Port FK, Levin NW, Turenne MN: Analysis of the association of dialyzer reuse practices and patient outcomes. Am J Kidney Dis 1994; 23:692-708.
6. Shaldon S: Dialyzer reuse: A practice that should be abandoned. Semin Dial 1993;6:11-12.
7. Shaldon S: Reuse of hemodialyzers. Nephrol Dial Transplant 1994;9:1226-1227.
8. Johnson RJ: Complement activation during extracorporeal therapy: Biochemistry, cell biology and clinical relevance. Nephrol Dial Transplant 1994;9[Suppl 2]:36-45.
9. Ward RA: Phagocytic cell function as an index of biocompatibility. Nephrol Dial Transplant 1994;9[Suppl 2]:46-56.
10. Pereira BJG, Dinarello CA: Production of pro-inflammatory cytokines and cytokine inhibitory proteins in patients on dialysis. Nephrol Dial Transplant 1994;9[Suppl 2]:60-71.
11. Cheung AK: Biocompatibility of hemodialysis membranes. J Am Soc Nephrol 1990;1:150-161.
12. Kant KS, Pollack VE, Cathey M, Goetz D, Berlin R: Multiple use of dialyzers: Safety and efficacy. Kidney Int 1981;19:728-738.
13. Hakim RM, Lowrie EG: Effect of dialyzer reuse on leukopenia, hypoxemia and total hemolytic complement system. Trans Am Soc Artif Intern Organs 1980;26:159-164.
14. Hoenich NA, Johnston SRD, Buckley P, Harden J, Ward MK, Kerr DNS: Haemodialysis reuse: Impact on function and biocompatibiolity. Int J Artif Org 1983;6:261-266.
15. Rancourt M, Senger K, DeOreo P: Cellulose membrane induced leukopenia after reprocessing with sodium hypochlorite. Trans Am Soc Artif Intern Organs 1984;30: 49-51.
16. Sherman RA, Cody RP, Rogers ME, Solanchick JC: The effect of dialyzer reuse on dialysis delivery. Am J Kidney Dis 1994;24:924-926.
17. Pereira BJG, King AJ, Falagas ME, Dinarello CA: Interleukin-1 receptor antagonist (IL-1Ra) and index of dialysis-induced interleukin-1 production. Nephron 1994; 67:358-361.
18. Pereira BJG, Poutsiaka DD, King AJ, et al.: In vitro production of interleukin-1 receptor antagonist in chronic renal failure, CAPD and HD. Kidney Int 1992; 42:1419-1424.
19. Pereira BJG, King AJ, Poutsiaka DD, Strom JA, Dinarello CA: Comparison of first and reuse of cuprophan membranes on interleukin-1 receptor antagonist and interleukin-1β production by blood mononuclear cells. Am J Kidney Dis 1993;22:288-295.
20. Tobias PS, Soldau K, Ulevitch FJ: Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem 1989;264:10867-10871.
21. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD 14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science (Washington DC) 1990;249:1431-1433.
22. Mathison JC, Wolfson E, Steinemann S, Tobias PS, Ulevitch RJ: Lipopolysaccharide (LPS) recognition in macrophages. Participation of LPS-binding protein and CD14 in LPS-induced adaptation in rabbit peritoneal exudate macrophages. J Clin Invest 1993;92:2053-2059.
23. Marra MN, Wilde CG, Collins MS, Snable JL, Thornton MB, Scott RW: The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol 1992;148:532-537.
24. Marra MN, Wilde CG, Griffith JE, Snable JL, Scott RW: Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol 1990;144:662-666.
25. Lonnemann G, Mahiout A, Schindler R, Colton CK: Pyrogen retention by the polyamide membranes. Contrib Nephrol 1992;96:47-63.
26. Poutsiaka DD, Clark BD, Vannier E, Dinarello CA: Production of interleukin-1 receptor antagonist and interleukin-1β by peripheral blood mononuclear cells is differentially regulated. Blood 1991;78:1275-1281.
27. Chenoweth DE, Hugli TE. Assays for chemotactic factors and anaphylatoxins. In: Nakamura RM, Dito WR, Tucker ES III, Eds. Immunological Analysis: Recent Progress in Diagnostic Laboratory Immunology. New York: Alan R. Liss; 1982:227-237.
28. Fleiss JL. Statistical Methods for Rates and Proportions. 2d Ed. New York: John Wiley; 1981.
29. Schindler R, Linnenweber S, Schulze M, et al.: Gene expression of interleukin-1β during hemodialysis. Kidney Int 1993;43:712-721.
30. Henderson LW, Koch KM, Dinarello CA, Shaldon S: Hemodialysis hypotension: The interleukin-1 hypothesis. Blood Purif 1983;1:3-8.
31. Association for Advancement of Medical Instrumentation. Recommended Practice for Reuse of Hemodialyzers. Arlington. VA: Association for Advancement of Medical Instrumentation; 1986.
32. Vanholder R, Ringoir S, Dhondt A, Hakim R: Phagocytosis in uremic and hemodialysis patients: A prospective and cross sectional study. Kidney Int 1991;39:320-327.
33. Zaoui P, Hakim R: The effects of the dialysis membrane on cytokine production. J Am Soc Nephrol 1994;4:1711-1718.
34. Lonnemann G, Barndt I, Kaever V, et al.: Impaired endotoxin-induces interleukin-1β secretion, not total production, of mononuclear cells from ESRD patients. Kidney Int 1995;47:1158-1167.
35. Himmelfarb J, Hakim RM: Biocompatibility and risk of infection in hemodialysis patients. Nephrol Dial Transplant 1994;9:138-144.
36. Vanholder R, Ringoir S: Infectious morbidity and defects of phagocytic function in end-stage renal disease: A review. J Am Soc Nephrol 1993;3:1541-1554.
37. Vanherweghem J-L, Tielemans C, Goldman M, Boelaert J: Infections in chronic hemodialysis patients. Semin Dial 1991;4:240-244.
38. Dinarello CA: The role of interleukin-1 in disease. N Engl J Med 1993;328:106-113.
39. Moldawer LL: Interleukin-1, TNFα and their naturally occurring antagonists in sepsis. Blood Purif 1993;11: 128-133.
40. Parillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471-1477.
41. Owen WF, Lew NL, Yan Liu SM, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentrations as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993;329:1001-1006.
42. Kaplan AA, Halley SE, Lapkin RA, Graeber CW: Dialysate protein losses with bleach reprocessed polysulfone dialyzers. Kidney Int 1995;47:573-578.